

- Levamisole, 727t, 2184, 2218t  
 Lev disease, 1471t  
 Levetiracetam  
   adverse effects of, 2554t, 2556  
   for cyclic vomiting syndrome, 261  
   for dementia, 175  
   for epilepsy, 2554t  
   for myoclonus, 2623  
   overdosage/poisoning with, 473e-10t, 2765t  
   for status epilepticus, 2558f  
   therapeutic monitoring of, 2765t  
 Levine's sign, 100, 1580  
 Levocardia, isolated, 1528  
 Levodopa  
   action of, 2614, 2614f  
   adverse effects of, 96e-4, 2614, 2618  
   for dystonia, 2621  
   for PD, 2613–2615, 2614f, 2616t, 2618  
 Levofloxacin  
   action of, 931t, 932–933, 943  
   adverse effects of, 2023  
   for *C. trachomatis* infection, 1171  
   for community-acquired pneumonia, 767t, 808t  
   for epididymitis, 872  
   in *H. pylori* eradication, 1042t  
   for HACEK endocarditis, 183e-1, 183e-2t  
   for health care–associated pneumonia, 767t, 812t  
   indications for, 941t, 943  
   for infections in cancer patient, 491  
   for infectious diarrhea, 857t  
   for intraabdominal infections, 767t  
   for *Legionella* infections, 1020t  
   for multidrug-resistant TB, 205e-6  
   for nongonococcal bacterial arthritis, 835  
   for osteomyelitis, 840t, 841t  
   for *P. aeruginosa* infections, 808t, 1045t  
   for pelvic inflammatory disease, 878  
   for peritonitis, 848  
   for plague prophylaxis, 1075t  
   for plague treatment, 261e-5, 261e-6, 1075  
   for pneumonia, 951–952  
   resistance to, 807, 931t, 941t  
   for sepsis/septic shock, 1757t  
   in traveler's medical kit, 797  
 Levomilnacipran, 2710t, 2717  
 Levonorgestrel, 2391  
 Levorphanol, 91t, 94  
 Levosimendan, 1510, 1510t  
 Levothyroxine  
   adverse effects of, 2292  
   in elderly patients, 2293  
   for hypothyroidism, 2292–2293  
   for myxedema coma, 2293  
   for nontoxic multinodular goiter, 2302  
   in pregnancy, 2293  
   for subacute thyroiditis, 2299  
   for thyroid cancer, 2295  
 Lewis blood group system, 138e-1, 138e-1t  
 Lewisite, 262e-1t  
 Lewis-Sumner syndrome, 2699  
 Lewy body(ies)  
   characteristics of, 2606  
   dementia with. *See* Dementia with Lewy bodies  
   prions and, 444e-8f, 453e-6  
 Leydig cell, 2358, 2358f  
 LFA-1 (leukocyte function-associated antigen), 372e-24t  
 LGI1 gene mutations, 2545t  
 LGMD (limb-girdle muscular dystrophy), 462e-6t, 462e-7t, 462e-8  
 LGV. *See* Lymphogranuloma venereum (LGV)  
 LH. *See* Luteinizing hormone (LH)  
 LH $\beta$  gene mutations, 2364, 2364t  
 Lhermitte's sign/symptom  
   in cervical spine lesions, 121, 161, 2535  
   in MS, 2535, 2663  
   radiation therapy–related, 622, 709  
   in spinal cord compression, 1790  
 LHR gene mutations, 2354t  
 LHX3 gene mutations, 2364, 2364t  
 Lialda, 1963  
 Libido  
   decreased, in malabsorption syndromes, 1946t  
   female, 330  
   male, 324  
 Libman-Sacks endocarditis, 2136  
 Lice  
   body (*Pediculus humanus*), 1146, 2745–2746  
   diseases carried by  
     epidemic typhus. *See* Epidemic (louse-borne) typhus  
     relapsing fever. *See* Relapsing fever  
   head (*Pediculus capitis*), 2745–2746, 2746f  
 Lichenification, 344f  
 Lichen myxedematosus, generalized (papular mucinosis), 364t, 365  
 Lichenoid lesions, 340t  
 Lichen planopilaris, 349  
 Lichen planus, 349  
   clinical features of, 347t  
     alopecia, 355, 355t  
     distribution, 341t, 342f, 349  
     esophageal, 257  
     morphology, 341t  
     oral manifestations, 46e-1f, 237, 239t, 240t  
     papules and plaques, 76e-3f, 349  
     papulosquamous lesions, 353, 353t  
     and plaques, 349  
   drug-related, 349  
   erosive, 46e-1f  
   HCV infection and, 349, 353, 2041  
   histologic features of, 347t  
   treatment of, 349  
 Lichen simplex chronicus, 342f, 345  
 Lichen tropicus, 479e-1  
 Licorice, 64e-8, 306, 307  
 Liddle's syndrome (pseudoaldosteronism)  
   clinical features of, 306, 322, 332e-9, 1620t  
   diagnosis of, 307, 2319  
   genetic considerations in, 306, 332e-7t, 1620t, 2318t, 2319  
   pathogenesis of, 322  
   pathophysiology of, 332e-9, 1621  
   treatment of, 307, 2319  
 Lidocaine  
   adverse effects of, 1480t  
   for arrhythmias, 1479t, 1498  
   for cardiac arrest, 1769f, 1770  
   dosage of, 1479t  
   for interstitial cystitis/bladder pain syndrome, 60e-4  
   for jellyfish stings, 2739  
   for marine envenomations, 2739, 2741  
   metabolism of, 34t  
   for neuropathy, 94, 2682t  
   for SUNCT/SUNA, 2596  
   therapeutic monitoring of, 2765t  
   for topical anesthesia in lumbar puncture, 443e-2  
 Lidoderm patch, 2682t  
 Life expectancy  
   at age 60, 93e-1t  
   at birth, 93e-1t, 93e-2  
   genetic considerations in, 85e-8  
   global burden of disease and, 9  
   global differences in, 13e-1–2, 13e-2f, 13e-3f, 93e-1t, 93e-2  
   screening procedures and increase in, 28t  
   trends in, 93e-3–4, 93e-3f  
   of women, 6e-1  
 Life history theory of aging, 94e-2  
 Lifestyle modifications  
   for atherosclerosis prevention, 291e-8t, 291e-9  
   for diabetes mellitus, 82  
   for GERD, 1908  
   for hypertension, 1622–1623, 1622t  
   for metabolic syndrome, 2452–2453  
   for NAFLD, 2056–2057  
   for obesity, 2394  
 Li-Fraumeni syndrome  
   clinical features of, 523, 599t  
   genetic considerations in, 101e-6t, 102e-2, 119e-1, 431t, 523, 599t  
   lung cancer risk in, 507  
 Light chain deposition disease/nephropathy  
   clinical features of, 1835t, 1845, 1859  
   diagnosis of, 1859  
   etiology of, 1859  
   pathophysiology of, 1859  
   renal biopsy in, 62e-7f, 1859f  
   treatment of, 1845, 1859  
 Light-headedness, 148  
 Likelihood ratio, 22, 23f  
 Lille score, 2053  
 LILRB2 gene, 1241t  
 Limaprost, 478e-5  
 Limb apraxia, 179  
 Limb dystonia, 2620  
 Limb-girdle muscular dystrophy (LGMD), 436t, 462e-6t, 462e-7t, 462e-8  
 Limbic encephalitis, 441e-1f, 444e-2t, 616, 616f, 2607  
 Limbic network/system, 182  
 Limb ischemia  
   acute, 1646  
   in peripheral artery disease. *See* Peripheral artery disease  
 Limb-kinetic apraxia, 179  
 Limb-sparing surgery, 119e-2, 119e-3  
 Limey bile, 2082  
 Limit dextrinosis (type III GSD), 432e-2t, 433e-2t, 433e-3, 436e-6f, 462e-14, 1565  
 Limulus ameobocyte lysate assay, 888  
 Linaclotide, 273, 274, 1970, 1970t  
 Linagliptin, 2414t  
 Lincosamides. *See* Clindamycin  
 Lindane, 2744, 2746  
 Linear IgA disease, 370t, 373, 379  
 Linear nevoid hypopigmentation (hypermelanosis of Ito), 357t, 359  
 Linear scleroderma, 376  
 Linezolid  
   action of, 205e-7, 931t, 932, 961  
   adverse effects of, 205e-7, 727t, 938t, 944, 961, 976  
   for burn-wound infection, 166e-3  
   for community-acquired pneumonia, 767t, 808t  
   drug interactions of, 205e-7, 939t, 944  
   for enterococcal infections, 975t, 976  
   for health care–associated pneumonia, 812t  
   indications for, 941t, 944  
   for MRSA infections, 767t, 808t, 962t  
   for *Nocardia* infections, 1087  
   for osteomyelitis, 841t  
   in pregnancy and lactation, 937t  
   resistance to, 931t, 934, 941t, 961  
   for staphylococcal infections, 832t, 961, 962t  
   for TB, 205e-7  
   for toxic shock syndrome, 963  
 LINGO-1, 444e-5  
 LINGO1 gene mutations, 2619  
 Linitis plastica, 534  
 Linkage analysis, 441–442, 442t  
 Linkage disequilibrium, 373e-3, 442, 442t  
 Lionfish sting, 2740  
 Liothyronine, 2292, 2306  
 Lipase, 2087t, 2088, 2100–2101  
 Lipedema, 1654  
 Lipemia retinalis, 2439  
 Lipid(s)  
   defects in metabolism of, 462e-15  
   deposits of, in familial hypercholesterolemia, 436e-4f  
   digestion and absorption of, 1935–1936, 1935t, 1936f  
   as energy source, 462e-14–15  
   neutral, disorders of, 432e-3t  
   production of, 2405  
   transport by lipoproteins, 2437, 2437f  
 Lipid A, 1752  
 Lipid mediator generation, 2115, 2115f  
 Lipid membrane microdomain (lipid raft), 372e-19  
 Lipid-modifying therapy. *See* Lipoprotein disorders, treatment of  
 Lipid polyene, 1352t  
 Lipid storage diseases, 367e-2–3, 367e-3t